



Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

July 28, 2025

DUBLIN, July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, August 12, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT / 9:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register [here](#). Those interested in listening to the conference call live via the internet may do so by [clicking here](#) or visiting the [Events and Presentation](#) page under the Investors Section on [Theravance Biopharma's website](#).

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through September 11, 2025.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver *Medicines that Make a Difference*[®] in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI[®] (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA[®], THERAVANCE[®] and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI[®] is a registered trademark of Viatrix Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:

investor_relations@theravance.com

650-808-4045

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-second-quarter-2025-financial-results-on-august-12-2025-302514625.html>

SOURCE Theravance Biopharma, Inc.